EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025
Description
DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Overview
EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) is a subtype of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. This receptor plays a critical role in cell growth and division. Mutations in EGFR lead to uncontrolled cell proliferation, contributing to cancer development. EGFR mutations are present in approximately 10-15% of NSCLC cases in Western populations and around 30-50% in Asian populations. This subtype of lung cancer is most commonly found in non-smokers, women, and patients with adenocarcinoma, a form of NSCLC.
Signs and symptoms of EGFR+ NSCLC are often subtle in the early stages, making early detection challenging. Symptoms may include persistent cough, chest pain, shortness of breath, wheezing, and unexplained weight loss. Some patients may experience coughing up blood (hemoptysis) or recurrent lung infections. As the disease progresses, the cancer may spread (metastasize) to other organs, leading to bone pain, headaches, or neurological issues.
Causes and risk factors for EGFR+ NSCLC are not fully understood, but certain factors increase the likelihood of developing this condition. A significant risk factor is genetic predisposition, as EGFR mutations can occur sporadically or be inherited. Environmental factors, such as exposure to secondhand smoke, air pollution, and radon, may also contribute. However, many patients with EGFR mutations have little or no smoking history, suggesting non-tobacco-related pathways in cancer development.
Diagnosis of EGFR+ NSCLC involves imaging tests such as chest X-rays, CT scans, and PET scans to identify suspicious lung nodules. A biopsy of lung tissue is essential for confirming NSCLC and conducting molecular testing to detect EGFR mutations. Liquid biopsy, analyzing circulating tumor DNA (ctDNA) from blood samples, is also emerging as a non-invasive diagnostic method. Accurate identification of EGFR mutations is crucial for tailoring targeted therapies.
Treatment for EGFR+ NSCLC typically involves targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs), which block the activity of the mutated receptor and inhibit cancer growth. First-generation TKIs like erlotinib and gefitinib, second-generation drugs like afatinib, and third-generation options such as osimertinib are commonly used. Osimertinib is often preferred due to its effectiveness against resistance mutations (T790M) and its ability to penetrate the central nervous system, addressing brain metastases. In cases where TKIs are no longer effective, chemotherapy, immunotherapy, or combination treatments may be considered. Ongoing research is exploring new therapies to improve outcomes for patients with EGFR+ NSCLC.
""EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape is provided which includes the disease overview and EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment guidelines. The assessment part of the report embraces, in depth EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Emerging Drugs
Further product details are provided in the report……..
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Therapeutic Assessment
This segment of the report provides insights about the different EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs.
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Overview
EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) is a subtype of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. This receptor plays a critical role in cell growth and division. Mutations in EGFR lead to uncontrolled cell proliferation, contributing to cancer development. EGFR mutations are present in approximately 10-15% of NSCLC cases in Western populations and around 30-50% in Asian populations. This subtype of lung cancer is most commonly found in non-smokers, women, and patients with adenocarcinoma, a form of NSCLC.
Signs and symptoms of EGFR+ NSCLC are often subtle in the early stages, making early detection challenging. Symptoms may include persistent cough, chest pain, shortness of breath, wheezing, and unexplained weight loss. Some patients may experience coughing up blood (hemoptysis) or recurrent lung infections. As the disease progresses, the cancer may spread (metastasize) to other organs, leading to bone pain, headaches, or neurological issues.
Causes and risk factors for EGFR+ NSCLC are not fully understood, but certain factors increase the likelihood of developing this condition. A significant risk factor is genetic predisposition, as EGFR mutations can occur sporadically or be inherited. Environmental factors, such as exposure to secondhand smoke, air pollution, and radon, may also contribute. However, many patients with EGFR mutations have little or no smoking history, suggesting non-tobacco-related pathways in cancer development.
Diagnosis of EGFR+ NSCLC involves imaging tests such as chest X-rays, CT scans, and PET scans to identify suspicious lung nodules. A biopsy of lung tissue is essential for confirming NSCLC and conducting molecular testing to detect EGFR mutations. Liquid biopsy, analyzing circulating tumor DNA (ctDNA) from blood samples, is also emerging as a non-invasive diagnostic method. Accurate identification of EGFR mutations is crucial for tailoring targeted therapies.
Treatment for EGFR+ NSCLC typically involves targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs), which block the activity of the mutated receptor and inhibit cancer growth. First-generation TKIs like erlotinib and gefitinib, second-generation drugs like afatinib, and third-generation options such as osimertinib are commonly used. Osimertinib is often preferred due to its effectiveness against resistance mutations (T790M) and its ability to penetrate the central nervous system, addressing brain metastases. In cases where TKIs are no longer effective, chemotherapy, immunotherapy, or combination treatments may be considered. Ongoing research is exploring new therapies to improve outcomes for patients with EGFR+ NSCLC.
""EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape is provided which includes the disease overview and EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment guidelines. The assessment part of the report embraces, in depth EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).
This segment of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Emerging Drugs
- CLN-081: Cullinan Oncology
- BPI-361175: Betta Pharmaceuticals
- G1T38: G1 Therapeutics
- JANX008: Janux Therapeutics
Further product details are provided in the report……..
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Therapeutic Assessment
This segment of the report provides insights about the different EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs.
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Report Insights
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs?
- How many EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cullinan Oncology
- Betta Pharmaceuticals
- G1 Therapeutics
- Janux Therapeutics
- Daiichi Sankyo Company
- Suzhou Puhe Pharmaceutical Technology
- Genor Biopharma
- J Ints Bio
- Avistone Pharmaceuticals
- Mythic Therapeutics
- CLN-081
- BPI-361175
- G1T38
- JANX008
- Patritumab Deruxtecan
- YK 209A
- GB 263 T
- JIN-A02
- PLB1004
- MYTX-011
Table of Contents
80 Pages
- Introduction
- Executive Summary
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC): Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- CLN-081: Cullinan Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- BPI-361175: Betta Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views
- EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
